The Gummy Project

In Preparation for Launch of the Gummy Project, Potent Ventures Activates Partnership with OCEARCH Through a Matching Gift Campaign Designed to Inspire the Global Community

Potent Ventures Inc. (CSE: POT) (FSE: 0OS) (OTCQB: POTVF) ("Potent" or the "Company") is excited to announce that the Company has activated its previously announced partnership with OCEARCH, a global non-profit organization conducting uprecedented research on shark populations in order to accelerate the ocean's return to balance and abundance.

In an effort to inspire communities to think globally and act locally when it comes to conservation, The Gummy Project is playing a key role in supporting OCEARCH's current collaborative study focused on the North Atlantic White Shark. To date, the study is over 80% complete, with Expedition Carolinas focused on the final piece of the puzzle, determining where these white sharks mate. The Gummy Project is pleased to donate $15,000 USD through a matching gift campaign. Kicking off March 22nd, 2022, OCEARCH supporters will be invited to support Expedition Carolinas in a unique way by supporting research in real-time.

"We are thrilled to put our partnership with OCEARCH into action and seize this opportunity to inspire a global network to participate in Expedition Carolinas through a unique giving campaign," said Mr. Charlie Lamb, CEO of The Gummy Project. "This is a strong first step for our Partnership with OCEARCH which we hope will inspire others to contribute to the Expedition Carolinas and OCEARCH."

"Everything that OCEARCH does is made possible through the support of our community. Their generosity allows us to educate thousands of students annually, advances cutting-edge research, and ultimately helps us restore balance and abundance to our oceans. We are very grateful to The Gummy Project for supporting our mission in a way that encourages others to deepen their support." - Stephanie K. Brown, Development Director.

About Expedition Carolinas

The OCEARCH Global Tracker led the team to the waters off the Carolina region where a dynamic confluence of currents and water temperature produces high productivity and potential food sources for sharks. OCEARCH's tracking data led them to the area off Cape Hatteras (where the "faunal break" divides the northern Atlantic coast and the southern Atlantic coast of the U.S.) where they watch the big males and females come together for a few weeks there before a number of the adult females head offshore on their migratory loops in the open Atlantic, where OCEARCH thinks they are gestating their developing young.

About OCEARCH

OCEARCH is a global non-profit organization conducting unprecedented research on our ocean's giants in order to help scientists collect previously unattainable data in the ocean. Our mission is to accelerate the ocean's return to balance and abundance through fearless innovations in critical scientific research, education, outreach, and policy using unique collaborations of individuals and organizations in the U.S and abroad. OCEARCH is recognized as a world leader in generating scientific data related to tracking (telemetry), and biological studies of keystone marine species such as great white sharks, tiger sharks, and more. OCEARCH provides a free open-sourced Shark Tracking service and app that allows scientists, educators, and fans alike to learn about the never before documented movements of our ocean's animals. OCEARCH has embarked on 40 research expeditions. Learn more at OCEARCH.ORG.

About Potent Ventures

We are a growing community of individuals and organizations who believe small contributions can add up to something big. We sell low sugar, plant based gummy products while raising money (and awareness) to support endangered keystone species. We are the only "better for you" candy company that is built to support our planet's most precious species and ecosystems, while educating our future generations on the steps we must take today, to ensure a viable tomorrow.

Charlie Lamb, President & CEO, Director
Telephone: 1(236) 317-2812 - Toll free 1(888) 556-9656
E-mail: investors@potent-ventures.com
www.shopgummies.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates", "may" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID-19, including the impact of COVID-19 on the Company's business, financial condition, and results of operations. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

Click here to connect with Potent Ventures Inc. (CSE: POT) (FSE: 0OS) (OTCQB: POTVF) to receive an Investor Presentation.

Source

The Conversation (0)
Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim in Early 2025

Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim in Early 2025

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF), also known as Sirona, is excited to share a new milestone in its journey. A recent exclusive video interview featuring Dr. Geraldine Deliencourt-Godefroy, Sirona's Chief Scientific Officer, has been released by the Investing News Network. In this interview, Dr. Deliencourt-Godefroy unveils Sirona's ambitious plans to introduce its innovative anti-aging product, GlycoProteMimTM, to the markets of North America and Europe in early 2025.

The interview provides an insightful look into the revolutionary potential of GlycoProteMim in the anti-aging sector. Viewers can access the full interview on the Investing News Network's website through this link: investingnews.com/sirona-biochem-eyes-2025-launch-of-new-anti-aging-product/

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE

Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline. Murdo Gordon executive vice president of Global Commercial Operations at Amgen, Jay Bradner executive vice president of Research and Development and chief scientific officer at Amgen, Vikram Karnani executive vice president of Global Commercial Operations and Medical Affairs (Rare Disease) at Amgen, and Paul Burton senior vice president and chief medical officer at Amgen, will participate in the conference call. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Provides Update on Loan

Sirona Biochem Provides Update on Loan

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") announce that, further to its news release on January 29, 2024, it has entered into an amendment to the demand grid promissory note dated September 22, 2023 (the " Amended Note ") with 0906462 B.C. Ltd. (the " Lender "). The Amended Note evidences a loan in the aggregate principal amount of up to $1,000,000 (the " Loan "). Pursuant to the terms and conditions of the Amended Note:

(a)   the Loan is repayable on demand by the Lender at any time following the one-year anniversary of the date of the applicable advance;

(b)   the Loan bears interest at a rate of 12% per annum, calculated yearly not in advance; and

(c)   the Company has agreed to, subject to TSX Venture Exchange approval (" TSXV Approval "), issue the Lender 450,000 common shares in the capital of the Company (" Bonus Shares ") at a price of $0.12 per Bonus Share, as consideration for the risks taken by the Lender in providing the Company the Loan.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Engages Global Beauty Consulting

Sirona Biochem Engages Global Beauty Consulting

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") has announced its partnership with Global Beauty Consulting Cosmetics Laboratory (GBC), under the leadership of CEO Gaël Boutry, a distinguished French formulator. GBC is currently developing an exclusive premium formulation for GlycoProteMim TM in anticipation of its launch in the first quarter of 2025.

GBC has a history of working with Sirona Biochem on the formulation of TFC-1067 for clinical development. This new venture is pivotal in building a brand and competitive product line that showcases GlycoProteMim's potent anti-aging benefits through its exclusive distribution brand Sirona Laboratories TM .

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Eyes 2025 Launch of New Anti-aging Product

Sirona Biochem Eyes 2025 Launch of New Anti-aging Product

Following successful clinical trials for its groundbreaking anti-aging and anti-wrinkle molecule, TFC-1326, Sirona Biochem (TSXV:SBM) is pursuing a path to commercialization for a final cosmetic product, according to the company’s chief scientific officer, Géraldine Deliencourt-Godefroy.

“We are still pursuing a final compound to launch on the market, which is pretty good because it will allow us to have a better control on the final product. We can launch fast on the market, we can generate revenue earlier and also the level of revenue will be higher,” Deliencourt-Godefroy said.

Sirona has already trademarked its anti-aging skincare ingredient, GlycoProteMim, as one of the first steps for commercialization. In January of this year, the company also launched a new cosmetics subsidiary, Sirona Laboratories, which is dedicated to maximizing the commercial potential of GlycoProteMim.

Keep reading...Show less

AMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE

- Amgen (NASDAQ:AMGN) will present at the 34 th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m. ET on Wednesday Feb. 14, 2024. Jay Bradner executive vice president of Research and Development and chief scientific officer at Amgen, Murdo Gordon executive vice president of Global Commerical Operations at Amgen, and Susan Sweeney senior vice president of Global Marketing, Access and Capabilities at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×